-
艾媒咨询|2021全球及中国大健康产业运行大数据及决策分析报告
本报告研究涉及企业/品牌/案例:阿里健康,联合丽格,恒瑞医药,白云山,平安好医生,111集团,新氧,药明巨诺,盘龙药业,先导药业,好大夫在线,优健康,春雨医生,丁香医生,微医
受到人口老龄化、居民患病比例增加等因素影响,国家医疗费用支出不断增加,属于刚性需求;同时,随着人们对健康标准的不断提高以及互联网医疗技术的发展,大健康产业会在相当长的时期内持续保持增长态势。数据显示,2020年中国的大健康产业营收规模超过7万亿元,预计2021年将达8万亿元,增幅达8.1%。其中,得益于大健康产业发展以及疫情期间医药需求增长,生物制药、医疗器械两大细分领域表现良好,成为2020年中国投资热度较高的新经济行业,投资项目金额分别为919亿元和273亿元。
Affected by the aging population and the increasing proportion of residents, the national medical expenditure is increasing, which belongs to the rigid demand; At the same time, with the continuous improvement of people's health standards and the development of internet medical technology, the big health industry will continue to grow for a long time. According to the data, the revenue of China's big health industry will exceed 7 trillion yuan in 2020, and it is expected to reach 8 trillion yuan in 2021, an increase of 8.1%. Among them, thanks to the development of big health industry and the growth of pharmaceutical demand during the epidemic period, biopharmaceuticals and medical devices have performed well, becoming China's new economy industry with high investment enthusiasm in 2020, with investment projects of 91.9 billion yuan and 27.3 billion yuan respectively. -
艾媒咨询|2020年中国细胞生物产业和商业应用分析报告
本报告研究涉及企业/品牌/案例:华夏源、复星医药。
中国细胞生物产业类型呈现多样化趋势,细胞生物临床研究不断深化,伴随生态合作的拓展将进一步加速细胞生物产业生态圈的形成,生态圈的完善将在很大限度上推动产业快速发展。数据显示,中国细胞治疗企业融资金额不断增加,从2014年的0.2亿元增长至2019年的28.9亿元。其中,2018年中国细胞治疗企业融资额同比增长706.8%,呈现迅猛发展态势。未来中国细胞生物产业的发展将充满机遇,同时也有挑战并存。后续产业的发展,将在5G、人工智能等新技术应用下加速升级。面临多端变化的市场格局,企业也应积极开展生态合作以及更为密切关注市场需求动向,将疗法和新一代医疗创新技术深度融合,实现市场产品多元化与差异化,并推出独特性的精准治疗,从而最大限度地释放产业价值。
The types of cell biological industry in China show a trend of diversification, and the deepening of cell biological clinical research will further accelerate the formation of the cell biological industry ecosystem with the expansion of ecological cooperation, and the improvement of the ecosystem will promote the rapid development of the industry to a large extent. Data show that the financing amount of Chinese cell therapy enterprises keeps increasing, from 20 million yuan in 2014 to 2.89 billion yuan in 2019. Among them, in 2018, the financing amount of Chinese cell therapy enterprises increased by 706.8% year on year, showing a rapid development trend. In the future, the development of China's cell biology industry will be full of opportunities and challenges. The development of subsequent industries will be accelerated with the application of new technologies such as 5G and ARTIFICIAL intelligence. In the face of the changing market pattern, enterprises should also actively carry out ecological cooperation and pay close attention to the trend of market demand, deeply integrate therapy and new-generation medical innovation technology, realize the diversification and differentiation of market products, and launch unique precision therapy, so as to maximize the release of industrial value. -
艾媒报告|2019-2021年中国中药材用户调研及延伸市场研究报告
本报告研究涉及企业/品牌/案例:同仁堂,片仔癀,东阿阿胶,太极集团,胡庆余堂,同仁牛黄清心丸,黄芪颗粒,雷氏丹参片,云峰气血口服液,太极五子衍宗丸,太极生力雄丸,仲景左归丸,一笑堂龟甲壳,白云山复方丹参片,天士力养血清脑颗粒,白云山夏桑菊颗粒,白云山板蓝根颗粒
随着居民消费水平的提升和健康保健意识的增强,总体健康需求在扩大,进而推动中医药市场的发展,2018年中国中药材市场规模达1246亿元,同比增长22.40%,预计到2024年,中药材市场规模将达2004亿元。
iiMedia Research(艾媒咨询)调查显示,2019年接近五成受访者购买过中药材,滋补养生和治病是购买中药材的两大目的。由于中医药应用范围广泛,中医药产业链不断扩展延伸,并加速扩展和整合。同仁堂、片仔癀、东阿阿胶等中药巨头企业纷纷布局中药材后市场,建设中药大健康产业,如植物提取物、保健食品、中药化妆品等,已成为我国生命健康产业中最具成长性的组成部分。
According to the iiMedia Research survey, nearly 50% of respondents have bought Chinese herbal medicines in 2019, and tonic sage and cure are the two main purposes for buying Chinese herbal medicines. Due to the wide range of applications of Chinese medicine, the Chinese medicine industry chain continues to expand and expand and accelerate the expansion and integration. Tongrentang, tablets, Dong'a gum and other Chinese medicine giant enterprises have laid out the chinese medicine after the market, the construction of chinese medicine large health industry, such as plant extracts, health food, Chinese medicine cosmetics, etc., has become China's life and health industry in the most growth component.
(以下为节选页,完整版共88页) -
艾媒报告 |2019年中国生物医药产业发展及舆论焦点分析报告
本报告研究涉及企业/品牌包括:Takeda、GSK、Sanofi、Celgene、Novartis、宝洁、CVC Fund VII、Shire、诺华OTC、Bioverativ、Juno Therapeutics、AveXis、Impact Biomedicines、Tesaro、Ablynx、默克OTC、Recordati控股公司FIMEI、复星医药、海正药业、康弘药业、泰合健康、齐鲁制药、复宏汉霖、信达生物、张江生物、恒瑞医药、三生国健、嘉和生物、百奥泰、深圳龙瑞、天坛生物、华兰生物、博雅生物、上海莱士、卫光生物、辽宁成大、智飞生物、康泰生物、沃森生物、利德曼、交大昂立、华润双鹤、力生制药、海欣股份、联环药业、白云山、中源协和、普洛药业
随着生物医药技术不断突破,中国生物医药产业快速发展,2018年,单抗、血液制品、疫苗等生物医药相关领域多家头部上市企业营收均超亿元,实现同比增长。iiMedia Research(艾媒咨询)监测发现,生物医药产业网络言值指数为49.7,网民评价态度偏向正面,上海网民对生物医药产业的关注度最高。未来,随着中国生物医药行业上市公司数量增多,行业与企业间竞争将更加激烈。
The scale of China's bio-pharmaceutical industry continues to grow, and the proportion of bio-pharmaceutical output in the pharmaceutical industry continues to rise. In 2017, the total output value of the bio-pharmaceutical industry in China's park was about 1.5 trillion yuan. At present, China's biomedical industry has formed three major clusters, including the Bohai Rim region, the Yangtze River Delta region and the Pearl River Delta region, and the industrial agglomeration effect is outstanding. China's bio-pharmaceutical industry is in a stage of rapid development. In 2018, many head-to-head listed companies in biomedical related fields such as monoclonal antibodies, blood products and vaccines all exceeded 100 million yuan, achieving year-on-year growth. According to iiMedia Research, netizens in Shanghai are most concerned about the biomedical industry, and 40.9% of netizens surveyed support the application of transgenic technology in the pharmaceutical field. Among the heads of monoclonal antibodies, blood products and vaccines, Fuhong Hanlin as well as Weiguang Bio and Lidmanthe has the best online reputation,iiMedia Consulting analysts believe that in the future, the combination of artificial intelligence with new drug research and the fierce competition among head enterprises is an important trend in the development of China's biomedical industry. -
艾媒报告 |2019全球及中国大健康产业运行大数据及决策分析报告
本报告研究涉及企业/品牌/案例:恒瑞医药,白云山,111集团,平安好医生,好大夫在线,优健康,春雨医生,微医,丁香医生,和美医疗,北大医疗,PHG,新氧,联合丽格,正广兴家庭医生,强森医疗,微脉,美中嘉和,零氪科技,中有精准医疗,思派网络,普瑞眼科,臻和科技,移宇科技,小鹿医馆,妈咪知道,八百方,京东医药,阿里健康大药房,1药网,一心堂,健一网,好药师,健客网,美丽神器,更美,悦美,美莱整形,伊美尔,丽都整形,芝星整形,欧华美科
大健康产业细分领域的垂直深化,推动了大健康产业格局的不断完善。受政策鼓励和资本推动的影响,2019年,大健康产业在患者服务类领域、医疗服务类领域、医药服务类领域、医疗美容类领域和医疗保健类领域等细分场景快速发展。以恒瑞医药、白云山为代表的传统医药上市公司和以平安好医生、111集团和新氧科技为代表的互联网医疗上市企业各自占据大健康产业领域的一席之地。艾媒商情舆情监测系统数据显示,受2018年和2019年上半年医疗领域负面舆情的影响,大健康产业各上市企业正从低谷平稳回升。艾媒咨询分析师认为,受社会医疗需求和国家政策的推动,大健康产业仍是未来投资的亮点。
The vertical deepening of the large health industry segment has promoted the continuous improvement of the pattern of the big health industry. Influenced by policy encouragement and capital promotion, in 2019, the big health industry developed rapidly in the sub-sectors such as patient service, medical services, medical services, medical and beauty, and health care. The traditional pharmaceutical listed companies represented by Hengrui Medicine and Baiyun Mountain and the Internet medical listed companies represented by Ping An Doctor, 111 Group and New Oxygen Technology each occupy a place in the field of large health industry. According to data from the Aibu Business Intelligence Monitoring System, the listed companies in the big health industry are recovering steadily from the bottom of the market due to the negative public sentiment in the medical field in the first half of 2018 and 2019. Ai Media Consulting analysts believe that the health industry is still the highlight of future investment, driven by social medical needs and national policies. -
艾媒研报 |2019H1新氧运行状况与商业趋势研究报告
本报告研究涉及企业/品牌/案例:腾讯,经纬中国,挚信资本,兰馨亚洲,安佰深中国,鼎晖投资,康辉医疗,瑞奇外科,星童医疗,美柚,V大夫,掌上糖医,药品终端网,GHG,Syneron Candela,郝海生物科技,华熙生物,复星医药,北京丽都医疗美容医院,深圳鹏爱医疗美容医院,更美,悦美,新氧,美黛拉,美呗,美丽神器
iiMedia Research(艾媒咨询)数据显示,2018年中国医美产业市场规模达2190亿元,预计2021年将突破3000亿元,行业增长快速,前景广阔。医美平台是医疗美容机构的获客新渠道,能够帮助医美机构实现精准营销,提升盈利空间。在行业加速发展的过程中,医美平台寡头格局逐步形成。新氧作为头部平台,已在用户数量、社区内容、医疗机构资源等方面有较多积累,在马太效应作用下,更易形成商业价值增长的良性循环。但随着规模扩张,平台上滋生了虚假日记、刷单等“灰色产业”,极大的损害了新氧的形象。然而机构和用户数量的增长不断增加新氧的审核难度,维护平台公信力的挑战升级。另外,随着互联网巨头以及老牌上市公司的入局,行业竞争加剧,新氧要面临来自用户规模、资金实力、技术实力、行业资源等多方面的围剿,未来发展道路阻碍重重。
According to iiMedia Research, in 2018, the scale of China's medical aesthetic market reached 219 billion yuan, and is expected to exceed 300 billion yuan in 2021. Chinese medical aesthetic industry is growing rapidly and considerably, bringing a broad prospect. The medical aesthetic platform is a new channel for medical aesthetic institutions, which can help medical institutions achieve accurate marketing and improve profitability. In the process of the accelerating development of the industry, a oligarchic pattern of the medical beauty platform has gradually formed. As a head platform, So-Young has accumulated a large scale of users, community content, medical institutions and other resources. Under the effect of Matthew effect, it is easier for So-Young to form a virtuous circle of commercial value growth. However, with the development, a ““gray industry““ consists of virtual holiday notes and brush sheets has emerged on the platform, which greatly damaged the image of So-Young. Meanwhile, the growth in the number of institutions and users increases the difficulty of platform audition, making the maintenance of its credibility even more challenging. In addition, with the Internet giants and established listed companies entering the game, the competition tends to be intensified. So-Young would have to face the pressure from user scale, financial strength, technical strength, and industry resources, which is rather challenging. -
艾媒报告|2019中国高考志愿填报与职业发展趋势分析报告(完整篇)
中国高考考生规模逐年增长,2018年中高考考生人数达975万人,河南、广东地区的考生竞争压力巨大,2018年河南和广东的高考考生分别为98.3万人和75.8万人,但一本录取率仅为12.5%和11.6%。专业选择方面,金融学、国际经济与贸易和财务管理专业仍为经典热门专业选择,北京、上海、广州、深圳等一线城市就业发展前景最好。新兴热门专业中,大数据、人工智能和智能制造等相关专业成未来高校培养人才的新方向。未来就业方面,百度、阿里、腾讯和华为等互联网巨头企业收割大量名校毕业生,国有商业银行偏爱财经类院校。5G、人工智能、商业航天、电子竞技等领域是新兴热门专业可就业领域。随着新一轮中国高考改革的全面铺开、本科录取批次合并、院校专业调整,中国高考志愿填报难度不断上升,但仅有15.0%的中国高考关注者非常了解高考志愿填报;并且他们的资讯获取渠道仍以校招生简章获取院校及专业信息,艾媒咨询分析师认为,中国高考关注者获取信息的渠道单一,获取的信息过时且缺乏专业解读,高考考生应提升高考志愿填报的重视程度,需要搜集更多相关信息,多向前辈、老师寻求意见,结合多种参考因素综合考虑。
The number of candidates for the Chinese college entrance examination has increased year by year. In 2018, the number of candidates for the college entrance examination reached 9.75 million. The competitive pressures of candidates in Henan and Guangdong are very high. In 2018, the candidates for college entrance examinations in Henan and Guangdong were 983,000 and 758,000 respectively, but one of them was admitted. The ratio is only 12.5% and 11.6%. In terms of professional choice, finance, international economics and trade, and financial management are still popular choices. First-tier cities such as Beijing, Shanghai, Guangzhou and Shenzhen have the best employment prospects. Among the emerging hot jobs, big data, artificial intelligence and smart manufacturing have become the new direction for future university talents. In terms of future employment, Internet giants such as Baidu, Ali, Tencent, and Huawei have already recruited a large number of graduates from prestigious universities, and state-owned commercial banks are more inclined to financial and economic institutions. 5G, artificial intelligence, commercial aerospace, e-sports and other fields are emerging in the hot professional employment field. With the new round of China's college entrance examination reform, the merger of undergraduate enrollment, and the adjustment of colleges and universities, the difficulty of filing for the Chinese college entrance examination is getting more and more difficult, but only 15.0% of the Chinese college entrance examinations are very familiar with the college entrance examination volunteers; their information acquisition channels still pass the school. Admissions guides receive university and professional information. Ai Media analysts believe that Chinese college entrance examination fans have a channel to obtain information, the information obtained is outdated, lack of professional explanation, candidates for college entrance examination should improve the college entrance examination volunteers. Pay attention to the need to collect more relevant information, more seniors, teachers seeking advice, and considering various reference factors. -
艾媒报告 |2018-2019中国医疗美容行业研究与产业链分析报告
本报告研究涉及企业/品牌包括:新氧、更美、悦美、美黛拉、美丽神器、美呗、南方医院、伊美尔、熙朵、碧莲盛、雍禾植发、科发源植发、新生植发、恒博医疗、昊海生物科技、华熙生物、复星医药、深圳鹏爱医疗美容医院、北京丽都医疗美容医院
中国医疗美容行业处于快速发展期,iiMedia Research(艾媒咨询)监测发现,2018年中国医美行业市场规模达2245亿元,牙齿美容及面部美容是医美市场的重要构成部分,占比分别达32.5%和35.3%。目前中国医美行业已形成生产商、医美机构、终端市场三大产业链环节,产业发展前景广阔,但作为新兴行业,中国医疗美容行业将面临着行业监管、公共关系危机、行业竞争激烈等几大风险。
Driven by the rise of the younger generation of consumer groups and the development of new models in the medical beauty industry, the penetration rate and consumer demand of China's medical beauty industry continue to rise. In 2018, the penetration rate of Chinese medical users reached 7.4%, and women were the main medical and aesthetic consumers. The proportion is 88.9%. At present, there are more than 10,000 registered medical and beauty institutions in China, and the industry is in a period of rapid development. iiMedia Research found that embedding, double eyelids, and full body fat filling are the favorite surgical items for Chinese women and medical consumers, while nasal synthesis, tautological fat, cheeks, hair transplants, etc. For the Chinese male medical beauty consumer's favorite surgical project, potential customers in China's medical beauty industry are most concerned about the safety of surgery, followed by medical qualifications and word of mouth and surgery prices. Medical beauty as an emerging industry, public relations crisis, strict industry supervision, lack of relevant professionals is a factor that restricts its development, and in the future, with the influx of capital from the industry, the competition in China's medical and aesthetic industry will become more intense.
- 1
- 2
没找到想要的报告?
扫码添加客服参与预约/定制,第一时间获取行业推荐报告!
智库热榜
艾媒咨询|2024-2025年中国银发经济投资前景分析报告
艾媒咨询|2024-2025年中国烘焙食品行业现状及趋势研究报告
艾媒咨询 | 2023-2024年中国休闲食品产业现状及消费行为数据研究报告
艾媒咨询|2024-2025年全球及中国新能源汽车行业消费趋势监测与案例研究报告
艾媒咨询 | 2023-2024年中国全域旅游产业运行数据及发展趋势研究报告
艾媒咨询 | 2024年中国家用美容仪行业消费者洞察研究报告
艾媒咨询|赵一鸣零食店消费行为洞察及行业趋势报告(2024)
艾媒咨询|2024年中国月饼行业创新发展研究报告
艾媒咨询 | 2024年中国数字中台市场研究报告
艾媒咨询|2023-2024年全球及中国跨境电商运营数据及典型企业分析研究报告
艾媒咨询|2024年中国家清产品消费趋势洞察报告